Research indicates that a balanced gut supports the whole body. More than 70% of the body's immune system is in the gut, and every gut microbiome is different.¹Â Traditional microbiome (stool) tests only look at the diversity of microbes present in the gut. Zinzino's Gut Health Test is the first of a new generation of gut health tests that measure gut function and whether these processes strengthen or strain the immune system.²Â Individuals can then use the test results to take proactive steps to restore t ...

BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening TrialExtensive Validation of BioMark's Comprehensive Metabolic Panel in German 10,000-Participant HANSE Study, within the context of an international consortium supported under the EUREKA Network.October 07, 2025 8:30 AM EDT | Source: BioMark Diagnostics, Inc.Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading dev ...

BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid BiopsyPioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets.September 29, 2025 8:30 AM EDT | Source: BioMark Diagnostics, Inc.Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technol ...

BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay August 05, 2025 8:30 AM EDT | Source: BioMark Diagnostics, Inc. Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy ...

Investor confidence remained high throughout the year, with BioMark's share price maintaining stability and posting modest gains. This performance stands in contrast to the downward trend observed across much of the diagnostics and biotech sectors, highlighting the Company's strategic position and strong fundamentals. "Our team remained focused on disciplined execution, data-driven strategy, and delivering tangible value," said Rashid Bux, BioMark's CEO. "That focus earned us the continued support of invest ...